Kaken Pharmaceutical Past Earnings Performance
Past criteria checks 4/6
Kaken Pharmaceutical's earnings have been declining at an average annual rate of -28.2%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been declining at an average rate of 5.1% per year. Kaken Pharmaceutical's return on equity is 5.1%, and it has net margins of 10.1%.
Key information
-28.2%
Earnings growth rate
-27.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | -5.1% |
| Return on equity | 5.1% |
| Net Margin | 10.1% |
| Next Earnings Update | 08 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Kaken Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 72,148 | 7,269 | 16,306 | 12,941 |
| 31 Mar 24 | 72,044 | 8,025 | 16,165 | 12,543 |
| 31 Dec 23 | 72,096 | 2,966 | 16,102 | 17,981 |
| 30 Sep 23 | 72,336 | 3,544 | 16,097 | 17,197 |
| 30 Jun 23 | 72,937 | 5,043 | 15,685 | 16,359 |
| 31 Mar 23 | 72,984 | 5,440 | 15,476 | 15,789 |
| 31 Dec 22 | 73,899 | 8,452 | 15,597 | 8,695 |
| 30 Sep 22 | 75,265 | 8,792 | 15,726 | 8,742 |
| 30 Jun 22 | 75,778 | 9,094 | 15,797 | 8,585 |
| 31 Mar 22 | 76,034 | 9,549 | 15,833 | 8,420 |
| 31 Dec 21 | 75,605 | 12,717 | 16,258 | 7,909 |
| 30 Sep 21 | 75,778 | 12,900 | 16,270 | 7,477 |
| 30 Jun 21 | 75,362 | 12,947 | 16,361 | 7,028 |
| 31 Mar 21 | 74,979 | 13,405 | 16,155 | 6,736 |
| 31 Dec 20 | 76,136 | 14,750 | 16,159 | 6,539 |
| 30 Sep 20 | 80,851 | 17,049 | 16,347 | 6,351 |
| 30 Jun 20 | 84,967 | 18,364 | 16,590 | 6,382 |
| 31 Mar 20 | 89,232 | 19,370 | 17,320 | 6,418 |
| 31 Dec 19 | 91,759 | 19,082 | 17,715 | 7,258 |
| 30 Sep 19 | 91,814 | 18,482 | 18,058 | 7,887 |
| 30 Jun 19 | 92,365 | 18,566 | 18,497 | 8,291 |
| 31 Mar 19 | 94,165 | 17,775 | 18,724 | 10,261 |
| 31 Dec 18 | 94,123 | 16,431 | 19,413 | 10,118 |
| 30 Sep 18 | 96,091 | 17,015 | 19,672 | 10,216 |
| 30 Jun 18 | 97,598 | 17,615 | 19,952 | 9,895 |
| 31 Mar 18 | 98,430 | 19,043 | 20,174 | 8,152 |
| 31 Dec 17 | 99,405 | 20,893 | 19,827 | 7,243 |
| 30 Sep 17 | 99,160 | 21,439 | 19,854 | 6,467 |
| 30 Jun 17 | 100,218 | 21,684 | 19,943 | 6,387 |
| 31 Mar 17 | 101,479 | 22,017 | 20,020 | 6,450 |
| 31 Dec 16 | 103,264 | 18,992 | 20,290 | 6,476 |
| 30 Sep 16 | 106,936 | 20,106 | 20,302 | 6,545 |
| 30 Jun 16 | 108,325 | 20,639 | 20,191 | 6,374 |
| 31 Mar 16 | 109,730 | 21,143 | 20,302 | 5,883 |
| 31 Dec 15 | 108,165 | 22,651 | 20,077 | 7,201 |
| 30 Sep 15 | 104,630 | 18,966 | 20,220 | 7,206 |
| 30 Jun 15 | 100,058 | 15,792 | 20,606 | 7,403 |
| 31 Mar 15 | 93,889 | 12,122 | 20,589 | 7,615 |
| 31 Dec 14 | 93,083 | 11,909 | 20,585 | 6,605 |
| 30 Sep 14 | 89,466 | 10,776 | 20,651 | 6,941 |
| 30 Jun 14 | 89,140 | 10,158 | 20,450 | 7,067 |
| 31 Mar 14 | 88,946 | 9,735 | 20,591 | 7,045 |
| 31 Dec 13 | 87,267 | 9,042 | 20,327 | 6,765 |
Quality Earnings: KKPC.F has high quality earnings.
Growing Profit Margin: KKPC.F's current net profit margins (10.1%) are higher than last year (6.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: KKPC.F's earnings have declined by 28.2% per year over the past 5 years.
Accelerating Growth: KKPC.F's earnings growth over the past year (44.1%) exceeds its 5-year average (-28.2% per year).
Earnings vs Industry: KKPC.F earnings growth over the past year (44.1%) exceeded the Pharmaceuticals industry 13%.
Return on Equity
High ROE: KKPC.F's Return on Equity (5.1%) is considered low.